Literature DB >> 25649668

Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.

Montse Guardiola1, Núria Plana1, Daiana Ibarretxe1, Anna Cabré1, Marta González1, Josep Ribalta1, Lluís Masana1.   

Abstract

The proprotein convertase subtilisin/kexin type 9 (PCSK9) gene regulates cholesterol homoeostasis by accelerating low-density lipoprotein receptor (LDLR) degradation resulting in the decreased catabolism of low-density lipoprotein (LDL) leading to hypercholesterolaemia. PCSK9 has also been related to other metabolic risk factors such as triglycerides (TGs) and glucose levels and body mass index (BMI). Therefore, our aim was to study the relationship between the PCSK9 and the lipid and lipoprotein profile. We studied 267 diabetic and metabolic syndrome patients who were not receiving any lipid-lowering therapy. We measured circulating lipids, cholesterol in remnant lipoproteins (RLPc) and PCSK9 levels. A detailed lipoprotein profile was determined based on NMR. Plasma PCSK9 levels were significantly and positively correlated with TG (r=0.136, P=0.033), total cholesterol (r=0.219, P<0.001) and apoB (apolipoprotein B; r=0.226, P=0.006) circulating levels and with an atherogenic profile of lipoprotein subclasses. In further detail, circulating PCSK9 levels were positively correlated with large very-low density lipoprotein (VLDL) particles, (r=0.210, P=0.001) and with their remnants, the intermediate-density lipoprotein (IDL) particles (r=0.206, P=0.001); positively correlated with smaller LDL particles (for small LDL: r=0.224, P<0.001; for medium small LDL: r=0.235, P<0.001; and for very small LDL: r=0.220, P<0.001); and with high-density lipoprotein (HDL) particles (r=0.146, P<0.001), which is mainly explained by the PCSK9 correlation with the smallest HDL particles (r=0.130, P=0.037). In addition, circulating PCSK9 levels were positively correlated with the pro-atherogenic circulating RLPc levels (r=0.171, P=0.006). All of the correlations were adjusted by age, gender and BMI. PCSK9 levels are significantly and positively correlated with atherogenic lipoproteins such as large VLDL, IDL, the smallest LDL, the smallest HDL particles and RLPc levels.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25649668     DOI: 10.1042/CS20140832

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  9 in total

1.  PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy.

Authors:  Arianna Toscano; Maria Cinquegrani; Michele Scuruchi; Antonino Di Pino; Salvatore Piro; Viviana Ferrara; Carmela Morace; Alberto Lo Gullo; Egidio Imbalzano; Francesco Purrello; Giovanni Squadrito; Roberto Scicali; Giuseppe Mandraffino
Journal:  Biomolecules       Date:  2022-04-09

2.  Improving Assessment of Lipoprotein Profile in Type 1 Diabetes by 1H NMR Spectroscopy.

Authors:  Laura Brugnara; Roger Mallol; Josep Ribalta; Maria Vinaixa; Serafín Murillo; Teresa Casserras; Montse Guardiola; Joan Carles Vallvé; Susana G Kalko; Xavier Correig; Anna Novials
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

3.  Systemic Inflammatory Markers Are Closely Associated with Atherogenic Lipoprotein Subfractions in Patients Undergoing Coronary Angiography.

Authors:  Yan Zhang; Sha Li; Rui-Xia Xu; Cheng-Gang Zhu; Yuan-Lin Guo; Na-Qiong Wu; Jing Sun; Jian-Jun Li
Journal:  Mediators Inflamm       Date:  2015-11-25       Impact factor: 4.711

4.  Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study.

Authors:  Massimiliano Ruscica; Nicola Ferri; Federica Fogacci; Martina Rosticci; Margherita Botta; Silvia Marchiano; Paolo Magni; Sergio D'Addato; Marina Giovannini; Claudio Borghi; Arrigo F G Cicero
Journal:  J Am Heart Assoc       Date:  2017-05-03       Impact factor: 5.501

Review 5.  COSMIC project: consensus on the objectives of the metabolic syndrome in clinic.

Authors:  Juan Pedro-Botet; Juan F Ascaso; Vivencio Barrios; Alejandro De la Sierra; Javier Escalada; Jesús Millán; Jose M Mostaza; Pablo Pérez-Martínez; Xavier Pintó; Jordi Salas-Salvadó; Pedro Valdivielso
Journal:  Diabetes Metab Syndr Obes       Date:  2018-10-31       Impact factor: 3.168

Review 6.  Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond.

Authors:  Thomas Grewal; Christa Buechler
Journal:  Int J Mol Sci       Date:  2022-01-19       Impact factor: 5.923

7.  Circulating Proprotein Convertase Subtilisin/Kexin type 9 level independently predicts incident cardiovascular events and all-cause mortality in hemodialysis black Africans patients.

Authors:  François-Pantaléon Musungayi Kajingulu; François Bompeka Lepira; Aliocha Natuhoyila Nkodila; Jean-Robert Rissassy Makulo; Vieux Momeme Mokoli; Pepe Mfutu Ekulu; Justine Busanga Bukabau; Yannick Mayamba Nlandu; Augustin Luzayadio Longo; Nazaire Mangani Nseka; Laura Labriola; Ernest Kiswaya Sumaili
Journal:  BMC Nephrol       Date:  2022-03-30       Impact factor: 2.388

8.  Multi-omic profiling of the leukemic microenvironment shows bone marrow interstitial fluid is distinct from peripheral blood plasma.

Authors:  Lorenz Nierves; Jian Guo; Siyuan Chen; Janice Tsui; Anuli C Uzozie; Jonathan W Bush; Tao Huan; Philipp F Lange
Journal:  Exp Hematol Oncol       Date:  2022-09-15

9.  Circulating PCSK9 Level and Risk of Cardiovascular Events and Death in Hemodialysis Patients.

Authors:  Hyeon Seok Hwang; Jin Sug Kim; Yang Gyun Kim; So-Young Lee; Shin Young Ahn; Hong Joo Lee; Dong-Young Lee; Sang Ho Lee; Ju Young Moon; Kyung Hwan Jeong
Journal:  J Clin Med       Date:  2020-01-17       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.